Alpha-ketoglutarate ameliorates age-related and surgery induced temporomandibular joint osteoarthritis via regulating IKK/NF-κB signaling

Therapeutic targets in aging-related osteoarthritis: A focus on the extracellular matrix homeostasis

Osteoarthritis (OA) represents a globally prevalent degenerative bone diseases and is the primary contributors to pain and disability among middle-aged and elderly people, thereby imposing significant social and economic burdens. When articular cartilage is in the aging environment, epigenetic modifications, DNA damage and mitochondrial dysfunction lead to cell senescence. Chondrocyte senescence has been identified as a pivotal event in this metabolic dysregulation of the extracellular matrix (ECM). It can affect the composition and structure of ECM, and the mechanical and biological signals transmitted by ECM to senescent chondrocytes affect their physiology and pathology. Over the past few decades, the role of ECM in aging-related OA has received increasing attention. In this review, we summarize the changes of cartilage's major ECM (type II collagen and aggrecan) and the interaction between aging and ECM in OA, and explore therapeutic strategies targeting cartilagae ECM, such as noncoding RNAs, small-molecule drugs, and mesenchymal stem cell (MSC)-derived extracellular vesicles for OA. The aim of this study was to elucidate the potential benefits of ECM-based therapies as novel strategies for the management of OA diseases.

Core-Shell Codelivery Nanocarrier Synergistically Regulates Cartilaginous Immune Microenvironment for Total Meniscus Replacement

Cartilage tissue engineering has made significant strides in clinical regenerative treatment. The success of cartilage regeneration critically depends on a favorable regenerative microenvironment by means of ideal bioactive scaffolds. However, total meniscus replacement frequently entails a harsh microenvironment of accompanying chronic inflammation and oxidative stress conditions after a massive injury, which extremely hinders tissue regenerative repair. Herein, a "core-shell" codelivery nanocarrier is developed to synergistically regulate the cartilaginous immune microenvironment (CIME) for total meniscus replacement. In this study, mesoporous silica nanoparticles are used to encapsulate an antioxidant and anti-inflammatory drug, Emodin, in the core and meanwhile modify a growth differentiation factor (GDF) by reversible disulfide bonds on the shell, together constructing a codelivery nanocarrier system (Em@MSN-GDF). The synergistic dual-drug release effectively reverses inflammation and oxidative microenvironment and is followed by successful promotion of fibrocartilage regeneration in vivo. Subsequently, Em@MSN-GDF-loaded cartilage-specific matrix hydrogels are combined with a meniscus-shaped polycaprolactone framework to construct a mechanically reinforced living meniscus substitute. As a result, rabbit experiments demonstrate that the codelivery nanocarrier system synergistically regulates the cartilaginous immune microenvironment, thereby achieving successful total meniscus replacement and fibrocartilage regeneration. The current study, therefore, offers a regenerative nanotreatment strategy to reverse the harsh microenvironment for total meniscus replacement.

Ectodysplasin-A deficiency exacerbates TMJOA by upregulating ATF4/Ihh signaling in mice

OBJECTIVE

Ectodysplasin-A (EDA) has been reported to be involved in mouse condylar development, but the specific functions of EDA in maintaining homeostasis of the temporomandibular joint (TMJ) remain unclear. This study aimed to explore the underlying roles and related mechanisms of EDA in temporomandibular joint osteoarthritis (TMJOA).

DESIGN

The TMJOA mouse model was established by unilateral discectomy and the alteration of EDA expression was detected. EDA knockout male mice and their wild-type male littermates were used to clarify the effect of EDA on TMJOA. Mouse condylar chondrocytes were extracted to explore the potential mechanisms. The effects of local injection of supplementary EDA on condyles were also evaluated morphologically and histologically.

RESULTS

The expression of EDA was downregulated in condylar cartilage after TMJOA modeling. EDA deficiency aggravated degeneration and inflammation of condylar cartilage in TMJOA mice. In vitro studies demonstrated that EDA deficiency upregulated the expression of inflammatory cytokines, while supplementary EDA exhibited anticatabolic and anti-inflammatory effects on tumor necrosis factor-α (TNFα)-treated mouse condylar chondrocytes. Mechanistically, EDA deficiency effectively activated activating transcription factor 4 (ATF4) to upregulate Indian hedgehog (Ihh) signaling pathway and thereby aggravated the inflammation. Inhibition of ATF4 resulted in blocking of Ihh signaling. The selective pharmacological inhibition of Ihh signaling attenuated TNF-α-induced chondrocyte destruction and the release of inflammatory cytokines. Furthermore, intra-articular application of EDA significantly alleviated the osteoarthritic cartilage destruction after discectomy.

CONCLUSIONS

EDA deficiency aggravated TMJOA by modulating ATF4/Ihh pathway, which confirmed the essential role of EDA in maintaining TMJ cartilage homeostasis and its potential application in TMJOA treatment.

Loss of SCRG1 in chondrocytes inhibits osteoarthritis by promoting autophagy activity in the temporomandibular joint through inhibition of neurokine receptors

BACKGROUND

To investigate in vitro how scrapie responsive gene 1 (SCRG1) contributes to the development of temporomandibular joint osteoarthritis (TMJOA).

METHODS

Western blotting was used to identify protein expression. Proinflammatory cytokine levels were assessed by means of an enzyme-linked immunosorbent test. In order to find out whether chondrocytes expressed protein light chain 3B (LC3B), immunofluorescence was utilized.

RESULTS

In the TMJOA in vitro model, hydrogen peroxide (H2O2) treatment increased the expression of SCRG1, stimulated chondrocyte catabolism and inflammatory response, and blocked autophagy. In chondrocytes, SCRG1 silencing reduces the inflammatory response, catabolism, and autophagy inhibition brought on by H2O2. Concurrently, H2O2 induction triggers the nuclear factor (NF)-κB pathway and nerve growth factor receptor (NGFR). When SCRG1 is downregulated, NGFR expression is inhibited and the NF-κB pathway is blocked.

CONCLUSIONS

By inhibiting NGFR and blocking the NF-κB pathway, knocking down SCRG1 can prevent H2O2-induced inflammatory response, metabolic breakdown and autophagy inhibition in chondrocytes.

CCL4/CCR5 regulates chondrocyte biology and OA progression

BACKGROUND

Osteoarthritis (OA) is a common musculoskeletal disorder characterized by chondrocyte apoptosis and extracellular matrix degradation. This study aimed to investigate the role of CCL4/CCR5 in regulating chondrocyte apoptosis and reactive oxygen species (ROS) levels in OA progression.

METHODS

Bioinformatics analysis was employed to identify CCL4 as the target gene, following which primary chondrocytes were treated with varying concentrations of CCL4. Apoptosis rate of chondrocytes and ROS levels were assessed using flow cytometry. The mechanism by which CCL4 regulated the extracellular matrix was investigated through Western blot and Immunofluorescence analyses. Additionally, maraviroc, a CCR5 inhibitor, was administered to chondrocytes in order to explore the potential signaling pathway of CCL4/CCR5.

RESULTS

Our study found that CCL4 was predominantly up-regulated among the top 10 hub genes identified in RNA-sequencing analysis. Validation through quantitative polymerase chain reaction (qPCR) confirmed elevated CCL4 expression in patients with Hip joint osteoarthritis, knee joint osteoarthritis, and facet joint osteoarthritis. The upregulation of CCL4 was associated with an increase in chondrocyte apoptosis and ROS levels. Mechanistically, CCL4, upon binding to its receptor CCR5, triggered the downstream phosphorylation of P65 in the nuclear factor-κB (NF-κB) signaling pathway. In vitro experiments demonstrated that treatment with maraviroc mitigated chondrocyte apoptosis, reduced intracellular ROS levels, and attenuated extracellular matrix degradation.

CONCLUSION

The study highlights the critical role of CCL4/CCR5 in modulating chondrocyte apoptosis and ROS levels in OA progression. Targeting this pathway may offer promising therapeutic interventions for mitigating the pathogenic mechanisms associated with OA.